Habib Zouali, Juliette Lemasson, Andreea Calugareanu, Christophe Battail, David Michonneau, Hélène le Buanec, Chloé Grolleau, Charles Cassius, Marie Robin, Marine Merandet, Gabor Dobos, Thibault Mahevas, Michel Rybojad, Adèle de Masson, Reyhan Amode, Anne Boland, Laurence Michel, Flore Sicre de Fontbrune, Régis Peffault de Latour, Patrick Bruneval, Hafid Ait-Oufella, Maxime Battistella, Marie Jachiet, Martine Bagot, Jean-François Deleuze, Gérard Socié, Jean-David Bouaziz
Cutaneous involvement of chronic graft-versus-host disease (cGVHD) has a wide range of manifestations including a lichenoid form with a currently assumed mixed Th1/Th17 signature and a sclerotic form with Th1 signature. Despite substantial heterogeneity of innate and adaptive immune cells recruited to the skin and of the different clinical manifestations, treatment depends mainly on the severity of the skin involvement and relies on systemic, high-dose glucocorticoids alone or in combination with a calcineurin inhibitor...
May 10, 2022: Blood Advances